28,886 Shares in Moderna, Inc. $MRNA Acquired by Freestone Capital Holdings LLC

Key Points

• Freestone Capital Holdings LLC has acquired a new stake in Moderna, purchasing 28,886 shares valued at approximately $782,000 in the first quarter.
• Analysts have set varying price targets for Moderna, with UBS Group reducing its target from $78.00 to $70.00 but retaining a "buy" rating, while Bank of America cut its target from $26.00 to $25.00, indicating an "underperform" rating.
• Moderna's recent earnings report revealed a loss of ($2.13) EPS for the quarter, which was better than analysts' estimates, and a revenue of $142 million, down 41.1% year-over-year.

Freestone Capital Holdings LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 28,886 shares of the company's stock, valued at approximately $782,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd acquired a new position in Moderna in the 1st quarter valued at approximately $25,000. Costello Asset Management INC acquired a new position in Moderna in the 1st quarter valued at approximately $30,000. Sentry Investment Management LLC acquired a new position in Moderna in the 1st quarter valued at approximately $31,000. Deseret Mutual Benefit Administrators increased its position in Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after acquiring an additional 392 shares during the period. Finally, Itau Unibanco Holding S.A. increased its position in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. UBS Group decreased their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research report on Friday, August 1st. Evercore ISI set a $32.00 price objective on shares of Moderna in a research report on Friday, August 1st. Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Bank of America decreased their price objective on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and a consensus price target of $43.59.

Moderna Trading Up 5.0%

NASDAQ:MRNA opened at $28.02 on Monday. The stock has a market capitalization of $10.90 billion, a price-to-earnings ratio of -3.72 and a beta of 1.83. The firm has a fifty day simple moving average of $29.20 and a two-hundred day simple moving average of $29.35. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same period last year, the company posted ($3.33) earnings per share. The business's quarterly revenue was down 41.1% on a year-over-year basis. Equities analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.